If you are a Healthcare Professional and you would like to log in to access this content, please click "Login".
You are now leaving the Lilly Medical Web site
Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Verzenios® ▼ (abemaciclib): Use in Pregnancy and Lactation and Effect on Fertility
In animal studies, Verzenios (abemaciclib) caused fetal harm and impaired fertility in males. Advise women not to breastfeed and to use contraception.
was teratogenic and caused decreased foetal weight at maternal
exposures similar to the recommended human dose.1
are no data from the use of abemaciclib in pregnant women. Studies in
animals have shown reproductive toxicity.1
is not recommended during pregnancy and in women of child-bearing
potential not using contraception.1
of childbearing potential should use highly effective contraception
methods (e.g. double‑barrier contraception) during treatment
and for at least 3 weeks after completing therapy.1
is unknown whether abemaciclib is excreted in human milk. A risk to
newborns/infants cannot be excluded. Patients receiving abemaciclib
should not breast-feed.1
effect of abemaciclib on fertility in humans is unknown. In animal
studies, no effects on female reproductive organs were observed.1
effects to the male reproductive tract in rats and dogs indicate that
abemaciclib may impair fertility in males.1
Verzenios [summary of product characteristics]. Eli Lilly Nederland
B.V., The Netherlands.
medicinal product is subject to additional monitoring. This will
allow quick identification of new safety information. Healthcare
professionals are asked to report any suspected adverse reactions.
Date of Last Review:January 27, 2020
Are you satisfied with this content?
Call or Email us
If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at email@example.com